Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2811 | Pandemic control measures Wiki | 1.00 |
| drug3533 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] Wiki | 1.00 |
| drug3534 | Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
Early administration of sarilumab in hospitalized patients infected with COVID-19 who have pulmonary infiltrates and are at high risk of unfavorable evolution could decrease/prevent progression to acute respiratory distress syndrome (ARDS) requiring high flow nasal oxygenation (HFNO) or either invasive or non-invasive mechanical ventilation.
Description: Proportion of patients requiring or time (in days) until required: High flow nasal oxygenation (HFNO) Non-invasive mechanical ventilation type BiPAP Non-invasive mechanical ventilation type CPAP Invasive mechanical ventilation
Measure: Ventilation requirements Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Crude mortality at 28 days
Measure: Crude mortality Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Time to clinical improvement: defined as the mean change or time in days from randomization to any of the following criteria: (i) improvement of two points on the ordinal scale of 7 points of severity or, (ii) hospital discharge with lifetime. The criteria reached before are used. The 7 point gravity scale includes the following categories: - Not hospitalized with normal activity - Not hospitalized but unable to have normal activity - Hospitalized, without requiring oxygen supplementation - Hospitalized, requiring oxygen supplementation - Hospitalized, requiring ONAF, non-invasive mechanical ventilation or both - Hospitalized requiring ECMO, invasive mechanical ventilation or both - Death
Measure: Time to clinical improvement Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Time (in days) until improvement in oxygenation for at least 48 hours: Time to verify an increase in the SpO2 / FiO2 ratio with respect to the worst SpO2 / FiO2 prior to treatment with Sarilumab and stratified according to levels of IL-6 or DD Time to absence of oxygen requirement to maintain saturation in ambient air ≥ 93% Number of days in need of supplemental oxygen
Measure: Time until improvement in oxygenation Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Proportion of patients requiring invasive mechanical ventilation in the trial
Measure: Proportion of patients requiring invasive mechanical ventilation Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Proportion of patients having negative COVID-19 CRP at each visit of the trial
Measure: Proportion of patients having negative COVID-19 CRP at each visit Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Mean of serum cytokine levels: the panel of cytokines to quantify; IL1-��, IL1-β, IL6, IL8, IL10, IL12, IL18, IL38, INFɣ, TNF��, CCL2, CCL3, CCL4, MIF and PAI-1
Measure: Mean of serum cytokine levels Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Incidence of adverse events related to medication and its administration
Measure: Adverse events related to medication and its administration Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Incidence in the appearance of serious bacterial, fungal or opportunistic infections in the subjects
Measure: Incidence in the appearance of serious bacterial, fungal or opportunistic infections Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Incidence of perforation of the gastrointestinal tract in subjects
Measure: Incidence of perforation of the gastrointestinal tract Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Leukocyte and neutrophil count mean
Measure: Leukocyte and neutrophil count Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Mean hemoglobin levels
Measure: Hemoglobin levels Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Platelet count mean
Measure: Platelet count Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Average levels of creatinemia
Measure: Levels of creatinemia Time: At day 28 or when the subject is discharged (whichever occurs first)Description: Average bilirubin levels
Measure: Bilirubin levels Time: At day 28 or when the subject is discharged (whichever occurs first)Description: ALT and AST average levels
Measure: ALT and AST levels Time: At day 28 or when the subject is discharged (whichever occurs first)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports